AKT1 and cancer: The Cancer Genome Altas (TCGA) data revealed the hyperactivation of phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) (PI3K/AKT/mTOR) pathway in nearly 60% of patients with OvCa [1].